|
CN106456751A
|
|
Methods of treating nail and scalp psoriasis
|
|
AU2013202140A1
|
|
Antibody formulation and therapeutic regimens
|
|
KR20120118036A
|
|
Antibody formulation and therapeutic regimens
|
|
AU2008266948A1
|
|
IL-17 heteromeric receptor complex
|
|
CN101541833A
|
|
Il-17 receptor a antigen binding proteins
|
|
AU2007200662A1
|
|
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
|
DK200401111A
|
|
Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders
|
|
AU2004202013A1
|
|
Production of pluripotent granulocyte colony-stimulating factor
|
|
DK200301683A
|
|
Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders
|
|
WO03020299A1
|
|
L-methionine as a stabilizer for nesp/epo in hsa-free formulations
|
|
US2002177688A1
|
|
Chemically-modified G-CSF
|
|
AU1974001A
|
|
Production of erythropoietin
|
|
ZA200100521B
|
|
Powdery preparation for mucosal administration containing polymeric medicine.
|
|
AU1110101A
|
|
Production of pluripotent granulocyte colony-stimulating factor
|
|
AU4252400A
|
|
Production of erythropoietin
|
|
EP1093818A1
|
|
Powdery preparation for mucosal administration containing polymeric medicine
|
|
AU6981798A
|
|
Production of erythropoietin
|
|
AU5204298A
|
|
Production of pluripotent granulocyte colony-stimulating factor
|
|
AU688723B3
|
|
Production of erythropoietin
|
|
US6166183A
|
|
Chemically-modified G-CSF
|
